Don't Miss Eric Boodman Font of despair: In the fierce competition for science funding, even a typeface glitch can be fatal
Don't Miss Helen Branswell, Adam Feuerstein and Damian Garde BIO in 30: A new biotech from Gates, Bradner on data science, & bienvenue à Cambridge
Don't Miss Damian Garde and Rebecca Robbins BIO in 30: The mechanics of drug prices, a new world record, & a very Canadian table hockey game
Don't Miss Helen Branswell, Adam Feuerstein and Rebecca Robbins BIO in 30: Combating sepsis, questioning Right to Try, & the existential dread of a mid-level exec
Don't Miss Casey Ross and Rebecca Robbins BIO in 30: Knock on ‘fast followers,’ all about Hong Kong, & Sculley’s next stop
Don't Miss Sharon Begley and Adam Feuerstein ASCO in 30: Wall Street’s reaction & patient-reported outcomes
Don't Miss Sharon Begley and Adam Feuerstein ASCO in 30: Immunotherapy controversy & less is just as good
In the Lab Carl Zimmer Shot through with microbes: How our bodies adapt to a hidden world of bacteria
Don't Miss Meghana Keshavan NIH’s Francis Collins on gene-editing, his truck-driving aspirations, and what he’d change about science
Politics Meghana Keshavan A rhyming year in review: Limericks that capture the best and worst of life sciences in 2017
